Aurenar announced a $5.7 million seed funding round to accelerate development of its single-use, non-invasive neuromodulation device, the V-Link. The company said the financing will be deployed to move the technology and corporate capabilities toward a pivotal-trial-ready stage.
The seed round was led by the American Heart Association Ventures’ Go Red for Women Venture Fund and Solas BioVentures, with participation from BJC Health and Kaleida Capital. Company leaders and investors framed the financing as a step toward broader clinical testing and commercial readiness for a device intended to address inflammation-related complications in critically ill patients.
Tracy Warren, senior managing director of the Go Red for Women Venture Fund, said the platform could improve recovery for patients generally and highlighted potential benefits for women, who often experience higher rates of post-stroke complications. She noted the technology’s potential for other conditions that trigger the body’s inflammatory response.
Aurenar’s V-Link delivers transuricalar vagus nerve stimulation (VNS) with a non-invasive, single-use approach. The company describes the therapy as a way to modulate the body’s inflammatory responses to injuries and neurologic events, citing subarachnoid hemorrhages as an example of a target condition.
Founder and CEO Eric Leuthardt, M.D., explained the origin of the idea for non-invasive VNS in critical care. He said the concept emerged nearly a decade ago and gained urgency after a colleague died in the intensive care unit from a delayed vasospasm following a ruptured cerebral aneurysm. The experience, he said, made clear there was a need for better tools to prevent inflammation-related complications in critically ill patients.
Leuthardt said his lab developed the technology and that neurosurgeon Anna Huguenard, M.D., organized the first pilot trial. He described early pilot data from Washington University in St. Louis as compelling, saying the approach appears to mitigate toxic inflammation in critically ill patients.
On June 30, the U.S. Food and Drug Administration granted the V-Link platform breakthrough device designation, a regulatory status intended to expedite development and review of devices that could provide more effective treatment for serious conditions. The company cited this designation in announcing the funding.
Aurenar referenced multiple pilot clinical trials conducted at Washington University that have evaluated the platform. According to the company, those early trials support the concept that non-invasive VNS can engage the brain’s natural mechanisms to modulate both systemic and central inflammation. Specific trial results, patient numbers, endpoints and timelines were not reported in the source.
Leuthardt said Aurenar’s near-term focus is on a spectrum of indications related to stroke, while noting the underlying technology is platform-based and could expand beyond neurologic disease. The company intends to use the newly raised capital to develop the product and organizational capabilities required to initiate pivotal studies.
Leuthardt emphasized that the body’s response to injury—regardless of cause—can elevate the risk of complications and death. He framed V-Link’s mechanism as addressing a “universal problem in critically ill patients,” where adverse events in the intensive care unit are often driven by elevated inflammation after the initial diagnosis and treatment.
Aurenar said the funding will support progress toward a pivotal-trial-ready company. Beyond that, the source did not report exact timelines for clinical milestones, regulatory filings, or commercialization plans. The company has identified stroke-related indications as initial targets but described the technology as applicable to other inflammation-triggering conditions.
This financing comes as part of early-stage investment activity in health technology and neuromodulation. The American Heart Association Ventures’ Go Red for Women Venture Fund framed its participation around the potential to reduce post-stroke complications and to accelerate innovations that disproportionately benefit women. Other specific market comparisons, valuation details, or follow-on financing plans were not provided in the source.
Aurenar was launched in 2024 by Eric Leuthardt, M.D. The company’s work has included laboratory development of a non-invasive vagus nerve stimulation approach and pilot clinical testing at Washington University in St. Louis. The company described the V-Link system as single-use and non-invasive, intended to enable the brain to modulate systemic and central inflammation in critically ill patients.
Aurenar’s $5.7 million seed round and the FDA’s June 30 breakthrough device designation mark key steps in advancing a non-invasive vagus nerve stimulation platform aimed at reducing inflammation-related complications after neurologic injury. The company plans to use the capital to prepare for pivotal trials, with an initial emphasis on stroke-related indications, while asserting the technology could scale to other conditions that provoke the body’s inflammatory response.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.